PolySciTech™ - Technical Blog

Technical Blog

John Garner, General Manager

A blog dedicated to answering technical questions in an open format relating to products from PolySciTech, a division of Akina, Inc.

Index

Select a topic to hide all other entries.
The most recent item is at the top.

PLGA-PEG-PLGA nanogel system used in development of brain cancer treatment.

Friday, December 20, 2024, 2:23 PM ET

Glioblastoma is a common form of brain cancer which is difficult to treat. One way to bypass the blood-brain-barrier to deliver therapeutics to the site is to implant a nanogel system into the cranial cavity directly. Researchers at Johns Hopkins University, St. John’s University, and OncoGone, Inc. used PLGA-PEG-PLGA ( cat# AK012, AK019) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to develop a pellet system for controlled delivery of Temozolomide and paclitaxel to brain tumors. This research holds promise to improve cancer therapy in the future. Read more: Slika, Hasan, Aanya Shahani, Kranthi Gattu, Varsha Mundrathi, Ameilia A. Solan, Brianna Gonzalez, Tasmima N. Haque et al. "Intracranial Nanogel Pellets Carrying Temozolomide and Paclitaxel for Adjuvant Brain Cancer Therapy." Molecular Pharmaceutics (2024). https://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.4c00708

“Glioblastoma multiforme is the most frequently diagnosed primary malignant brain tumor. Despite multimodal therapy with surgical resection, radiation therapy, and chemotherapy, recurrence of the tumor is almost always guaranteed due to the infiltrative nature of the disease. Moreover, the blood brain barrier imparts an additional layer of complexity by impeding the delivery of therapeutic agents to the tumor, hence limiting the efficacy of systemically delivered drugs. Hence, to overcome this obstacle and avoid treatment resistance, the local delivery of combination therapies has risen as an appealing adjuvant treatment. The present study describes the creation of a novel PLGA–PEG-PLGA-based nanogel pellet system for the interstitial delivery of Temozolomide (TMZ) and paclitaxel (PTX) to the brain. The nanogel pellet was shown to be stable as a pellet at ambient temperature, absorb water, change to a gel formulation at physiological temperature, and achieve gradual long-term release of TMZ and PTX in vitro. Additionally, in vivo testing of the TMZ/PTX-loaded nanogel pellets in an orthotopic CT2A mouse model and an orthotopic 9L rat model has shown an acceptable safety profile when implanted intracranially and a significant improvement in overall survival.”

PLGA-PEG-PLGA (Cat# AK012, AK019): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AK012#h

https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AK019#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM Polymer Products: https://akinainc.com/polyscitech/products/ashland/

Fluorescent PLGA from PolySciTech used in development of carrier system for cell immunotherapy as treatment of infection.

Friday, December 13, 2024, 11:15 AM ET

Although periodontitis is an oral infection affecting teeth, it has been strongly associated with diseases of significantly higher morbidity and mortality such as cardiovascular disease, diabetes, and rheumatoid arthritis. Macrophages (immune cells) can be directed to control immune response as well as healing and other biological processes by attaching cellular backpacks to them. Researchers at Harvard University, Massachusetts Institute of Technology, and Niigata University used PLGA-rhodamine and PLGA-CY5 (AV011, AV034) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to develop particles which can control macrophage behavior. This research holds promise to treat a wide range of disease states. Read more: Nakajima, Mayuka, Neha Kapate, John R. Clegg, Mayumi Ikeda-Imafuku, Kyung Soo Park, Ninad Kumbhojkar, Vinny Chandran Suja et al. "Backpack-carrying macrophage immunotherapy for periodontitis." Journal of Controlled Release 377 (2025): 315-323. https://www.sciencedirect.com/science/article/pii/S016836592400782X

“Highlights: M2 macrophages can suppress inflammation in periodontitis. IL-4 loaded cellular backpacks (BPs) were engineered for maintaining macrophages in M2 phenotype. M2 cells carrying IL-4 BPs (BP-M2 cells) were injected into the inflamed gingiva. M2 cells remained in the injected tissue and their therapeutic efficacy was observed. BP-M2 cells offer a promising local therapy for treating periodontitis. Abstract: Cell immunotherapy is a promising therapeutic modality to combat unmet medical needs. Macrophages offer a prominent cell therapy modality since their phenotypic plasticity allows them to perform a variety of roles including defending against pathogens, inducing/suppressing adaptive immunity, and aiding in wound healing. At the same time, this plasticity is a major hurdle in implementation of macrophage therapy. This hurdle can be overcome by cellular backpacks (BPs), discoidal particles that adhere on the macrophage surface and regulate M1/M2 phenotypic shift in an environment-independent manner. In this study, we engineered IL-4 BPs for maintaining macrophages in the M2 phenotype to regulate excess inflammation in periodontitis, a major oral infectious disease. IL-4 BPs induced and maintained M2 phenotype in macrophages in vitro for several days. After injection of macrophages carrying IL-4 BPs into the gingiva, the cells stayed in the tissue for over 5 days and maintained the M2 phenotype in the disease sites. Furthermore, treatment with IL-4 BP-macrophages significantly suppressed the disease progression. Altogether, a treatment with BP-carrying macrophages offers a promising local therapy against periodontitis.”

PLGA-Rhodamine (Cat# AV011): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AV011#h

PLGA-Rhodamine (Cat# AV034): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AV034#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM Polymer Products: https://akinainc.com/polyscitech/products/ashland/

mPEG-PLGA from PolySciTech used in development of advanced radiotherapy of brain cancer

Monday, November 25, 2024, 9:29 AM ET

Glioblastoma is a form of brain cancer which has high mortality and limited treatment options. Currently only surgery and radiotherapy are available as treatments. Radiotherapy can be enhanced by delivery of radiosensitizers to the glioblastoma region. Researchers at Fuzhou University, Fujian Medical University School, and Fujian Agriculture and Forestry University utilized mPEG-PLGA (AK037) to delivery hemin to glioblastoma to improve the efficacy of radiotherapy. This research holds promise to improve therapy of brain tumors in the future. Read more: Yang, Bo, Xiaohang Jiang, Yifan Liu, Guangwei Zheng, Yanjuan Li, Fuli Xin, and Feng Lu. "Erythrocyte Membrane-Camouflaged Hemin-Based Nanoplatform for Radiotherapy of Glioblastoma." ACS Applied Nano Materials (2024). https://pubs.acs.org/doi/abs/10.1021/acsanm.4c04992

“Glioblastoma, accounting for 44% of all malignant brain tumors, is characterized by a dismal prognosis due to high mortality, recurrence, and limited survival time. Current standard treatment, radiotherapy, is resistant to the tumor hypoxic microenvironment, which reduces the effect of radiotherapy. Here, we present a nanoplatform, PLGA-Hemin@RBCM (PHR), which leverages the catalase mimetic activity of hemin to convert tumor-elevated H2O2 into oxygen and hydroxyl radicals, improving tumor oxygenation and enhancing radiotherapy sensitivity. The PEG-PLGA nanomicelle delivery platform improves the biocompatibility and stability of the drug and delays the release of the drug. Camouflaging the nanoparticles with red blood cell membranes not only avoids immune clearance but also prolongs circulation time and enhances tumor accumulation via the EPR effect. In vitro and in vivo studies demonstrate the efficacy of our nanoplatform, offering a promising therapeutic strategy for glioblastoma management in the clinic.”

mPEG-PLGA (Cat# AK037): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AK037#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

Extrusion Process Optimization Research Performed Using Ashland PLGA Available for Distribution through PolySciTech

Tuesday, November 12, 2024, 3:57 PM ET

Through a partnership with Ashland, PolySciTech provides distribution of PLGA products for non-clinical development purposes (https://akinainc.com/polyscitech/products/ashland/). Recently several of these polymers were utilized in research on hot-melt extrusion processing for development of long-acting implants. This research holds promise to provide for LAIs that can achieve desired drug release profiles for long-term patient care. Read more: Yang, Fengyuan, Ryan Stahnke, Kamaru Lawal, Cory Mahnen, Patrick Duffy, Shuyu Xu, and Thomas Durig. "Development of poly (lactic-co-glycolic acid)(PLGA) based implants using hot melt extrusion (HME) for sustained release of drugs: The impacts of PLGA’s material characteristics." International Journal of Pharmaceutics 663 (2024): 124556. https://www.sciencedirect.com/science/article/pii/S0378517324007907

“Hot melt extrusion (HME) processed Poly (lactic-co-glycolic acid) (PLGA) implant is one of the commercialized drug delivery products, which has solid, well-designed shape and rigid structures that afford efficient locoregional drug delivery on the spot of interest for months. In general, there are a variety of material, processing, and physiological factors that impact the degradation rates of PLGA-based implants and concurrent drug release kinetics. The objective of this study was to investigate the impacts of PLGA’s material characteristics on PLGA degradation and subsequent drug release behavior from the implants. Three model drugs (Dexamethasone, Carbamazepine, and Metformin hydrochloride) with different water solubility and property were formulated with different grades of PLGAs possessing distinct co-polymer ratios, molecular weights, end groups, and levels of residual monomer (high/ViatelTM and low/ ViatelTM Ultrapure). Physicochemical characterizations revealed that the plasticity of PLGA was inversely proportional to its molecular weight; moreover, the residual monomer could impose a plasticizing effect on PLGA, which increased its thermal plasticity and enhanced its thermal processability. Although the morphology and microstructure of the implants were affected by many factors, such as processing parameters, polymer and drug particle size and distribution, polymer properties and polymer-drug interactions, implants prepared with ViatelTM PLGA showed a smoother surface and a stronger PLGA-drug intimacy than the implants with ViatelTM Ultrapure PLGA, due to the higher plasticity of the ViatelTM PLGA. Subsequently, the implants with ViatelTM PLGA exhibited less burst release than implants with ViatelTM Ultrapure PLGA, however, their onset and progress of the lag and substantial release phases were shorter and faster than the ViatelTM Ultrapure PLGA-based implants, owing to the residual monomer accelerated the water diffusion and autocatalyzed PLGA hydrolysis. Even though the drug release profiles were also influenced by other factors, such as composition, drug properties and polymer-drug interaction, all three cases revealed that the residual monomer accelerated the swelling and degradation of PLGA and impaired the implant’s integrity, which could negatively affect the subsequent drug release behavior and performance of the implants. These results provided insights to formulators on rational PLGA implant design and polymer selection.”

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

Video: https://youtu.be/h2JEHB5Uvz0

mPEG-PLGA from PolySciTech used in development of mRNA delivery system for cancer therapy.

Tuesday, November 5, 2024, 4:09 PM ET

The ability to deliver mRNA to cells enable direct formation of desired therapeutic or immune-controlling proteins at the cells directly. This has previously been used as part of the covid vaccine though the technique can also be used for therapies against cancer as well. Researchers at University of Ottawa used mPEG-PLGA (cat# AK010) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to develop particles to deliver mRNA to tumor cells. This research holds promise to provide for further treatment options for cancer in the future. Read more: El-Sahli, Sara, Shireesha Manturthi, Emma Durocher, Yuxia Bo, Alexandra Akman, Christina Sannan, Melanie Kirkby et al. "Nanoparticle-mediated mRNA delivery to TNBC PDX tumors." (2024). https://www.researchsquare.com/article/rs-4892937/latest

“mRNA-based therapies can overcome several challenges faced by traditional therapies in treating a variety of diseases by selectively modulating genes/proteins without genomic integration. However, due to mRNA’s poor stability and inherent limitations, nanoparticle (NP) platforms have been developed to deliver functional mRNA into cells. In cancer treatment, mRNA technology has multiple applications, such as restoration of tumor suppressors and activating anti-tumor immunity. Most of these applications have been evaluated using simple cell line-based tumor models, which failed to represent the complexity, heterogeneity, and 3D architecture of patient tumors. This discrepancy has led to inconsistencies and failures in clinical translation. Compared to cell line models, Patient-derived xenograft (PDX) models more accurately represent patient tumors and are better suitable for modeling. Therefore, for the first time, this study employed two different TNBC PDX tumors to examine the effects of mRNA-NPs. mRNA-NPs are developed using EGFP-mRNA as a model and studied in TNBC cell lines, ex vivo TNBC PDX organotypic slice cultures, and in vivoTNBC PDX tumors. Our findings show that NPs can effectively accumulate in tumors after intravenous administration, protecting and delivering mRNA to PDX tumors with different genetic and chemosensitivity backgrounds. These studies offer more clinically relevant modeling systems for mRNA nanotherapies for cancer applications.”

mPEG-PLGA (Cat# AK010): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AK010#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

PLGA-Rhodamine from PolySciTech used in development of CBD and BDNF brain delivery system for treatment of Alzheimer's

Friday, October 25, 2024, 4:10 PM ET

Alzheimer’s disease is a chronic, degenerative condition which leads to memory loss. Researchers at North Dakota State University used PLGA-Rhodamine (AV011) and PLGA (AP018) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to develop nanoparticles targeting the brain. These were used for the delivery of Cannabidiol (CBD) (anti-inflammatory) and brain-derived neurotrophic factor (BDNF). This research holds promise to provide for treatment against Alzheimer’s disease. Read more: Mahanta, Arun Kumar, Bivek Chaulagain, Riddhi Trivedi, and Jagdish Singh. "Mannose-Functionalized Chitosan-Coated PLGA Nanoparticles for Brain-Targeted Codelivery of CBD and BDNF for the Treatment of Alzheimer’s Disease." ACS Chemical Neuroscience (2024). https://pubs.acs.org/doi/abs/10.1021/acschemneuro.4c00392

“Alzheimer’s disease (AD) is a common neurodegenerative disease causing cognitive and memory decline. AD is characterized by the deposition of amyloid-β and hypophosphorylated forms of tau protein. AD brains are found to be associated with neurodegeneration, oxidative stress, and inflammation. Cannabidiol (CBD) shows neuroprotective, antioxidant, and anti-inflammatory properties and simultaneously reduces amyloid-β production and tau hyperphosphorylation. The brain-derived neurotrophic factor (BDNF) plays a vital role in the development and maintenance of the plasticity of the central nervous system. A decline of BDNF levels in AD patients results in reduced plasticity and neuronal cell death. Current therapeutics against AD are limited to only symptomatic relief, necessitating a therapeutic strategy that reverses cognitive decline. In this scenario, combination therapy of CBD and BDNF could be a fruitful strategy for the treatment of AD. We designed mannose-conjugated chitosan-coated poly(d,l-lactide-co-glycolide (PLGA) (CHTMAN-PLGA) nanoparticles for the codelivery of CBD and BDNF to the brain. Chitosan is modified with mannose to specifically target the glucose transporter-1 (GLUT-1) receptor abundantly present in the blood–brain barrier for selectively delivering therapeutics to the brain. The CBD-encapsulated nanoparticles showed an average hydrodynamic diameter of 306 ± 8.12 nm and a zeta potential of 31.7 ± 1.53 mV. The coated nanoparticles prolonged encapsulated CBD release from the PLGA matrix. The coated nanoparticles exhibited sustained release of CBD for up to 22 days with 91.68 ± 2.91% release of the encapsulated drug. The coated nanoparticles, which had a high positive zeta potential (31.7 ± 1.53 mV), encapsulated the plasmid DNA. The qualitative transfection efficiency was investigated using CHTMAN-PLGA-CBD/pGFP in bEND.3, primary astrocytes, and primary neurons, while the quantitative transfection efficiency of the delivery system was determined using CHTMAN-PLGA-CBD/pBDNF. In vitro, the pBDNF transfection study revealed that the BDNF expression was 4-fold higher for CHTMAN-PLGA-CBD/pBDNF than for naked pBDNF in all of the cell lines. The cytotoxicity and hemocompatibility of the designed nanoparticles were tested in bEND.3 cells and red blood cells, respectively, and the nanoparticles were found to be nontoxic and hemocompatible. Hence, mannose-conjugated chitosan-coated PLGA nanoparticles could be useful as brain-targeting delivery vehicles for the codelivery of CBD and BDNF for possible AD treatment.”

PLGA-Rhodamine (Cat# AV011): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AV011#h

PLGA (Cat# AP018): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AP018#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

mPEG-PLA from PolySciTech used in development of phototherapy treatment of cancer.

Friday, October 25, 2024, 4:09 PM ET

A common problem with chemotherapy is the non-specific delivery of drugs to healthy cells which causes systemic side effects. Phototherapy uses a combination of an injectable formulation with an illumination trigger applied to the site of the tumor. The formulation remains relatively inert until it interacts with the light to deliver the drug. Researchers at The State University of New York used mPEG-PLA (AK009) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to develop nanoparticles which can be triggered to release paclitaxel upon exposure to illumination. This research holds promise to provide treatment of cancer in the future. Read more: Giram, Prabhanjan, Ganesh Bist, Sukyung Woo, Elizabeth Wohlfert, Roberto Pili, and Youngjae You. "Prodrugs of paclitaxel improve in situ photo‐vaccination." Photochemistry and Photobiology (2024). https://onlinelibrary.wiley.com/doi/abs/10.1111/php.14025

“Abstract: Photodynamic therapy (PDT) effectively kills cancer cells and initiates immune responses that promote anticancer effects locally and systemically. Primarily developed for local and regional cancers, the potential of PDT for systemic antitumor effects [in situ photo-vaccination (ISPV)] remains underexplored. This study investigates: (1) the comparative effectiveness of paclitaxel (PTX) prodrug [Pc-(L-PTX)2] for PDT and site-specific PTX effects versus its pseudo-prodrug [Pc-(NCL-PTX)2] for PDT combined with checkpoint inhibitors; (2) mechanisms driving systemic antitumor effects; and (3) the prophylactic impact on preventing cancer recurrence. A bilateral tumor model was established in BALB/c mice through subcutaneous injection of CT26 cells. Mice received the PTX prodrug (0.5 μmole kg−1, i.v.), and tumors were treated with a 690-nm laser (75 mW cm−2 for 30 min, drug-light interval 0.5 h, light does 135 J cm−1), followed by anti-CTLA-4 (100 μg dose−1, i.p.) on days 1, 4, and 7. Notable enhancement in both local and systemic antitumor effectiveness was observed with [Pc-(L-PTX)2] compared to [Pc-(NCL-PTX)2] with checkpoint inhibitor. Immune cell depletion and immunohistochemistry confirmed neutrophils and CD8+ T cells are effectors for systemic antitumor effects. Treatment-induced immune memory resisted newly rechallenged CT26, showcasing prophylactic benefits. ISPV with a PTX prodrug and anti-CTLA-4 is a promising approach for treating metastatic cancers and preventing recurrence.”

mPEG-PLA (Cat# AK009): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AK009#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

PLGA-PEG-COOH from Akina used in development of nanoparticles for drug delivery to colorectal cancer.

Monday, October 21, 2024, 4:45 PM ET

Colorectal cancer is a prevalent disease with estimated 1.93 million new cases in 2020. Researchers at Nazarbayev University and Al-Farabi Kazakh National University used PLGA-PEG-COOH (AI078) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to develop CASIN loaded nanoparticles for targeted therapy of colorectal cancer. This research holds promise to provide for treatment of cancer. Read more: Kadyr, Sanazar, Altyn Zhuraliyeva, Aislu Yermekova, Aigerim Makhambetova, Daulet B. Kaldybekov, Ellina A. Mun, Denis Bulanin, Sholpan N. Askarova, and Bauyrzhan A. Umbayev. "PLGA-PEG Nanoparticles Loaded with Cdc42 Inhibitor for Colorectal Cancer Targeted Therapy." Pharmaceutics 16, no. 10 (2024): 1301. https://www.mdpi.com/1999-4923/16/10/1301

“Abstract: Background/Objectives: An inhibitor of small Rho GTPase Cdc42, CASIN, has been shown to reduce cancer cell proliferation, migration, and invasion, yet it has several limitations, including rapid drug elimination and low bioavailability, which prevents its systemic administration. In this study, we designed and characterized a nanoparticle-based delivery system for CASIN encapsulated within poly(lactide-co-glycolide)-block-poly(ethylene glycol)-carboxylic acid endcap nanoparticles (PLGA-PEG-COOH NPs) for targeted inhibition of Cdc42 activity in colon cancer. Methods: We applied DLS, TEM, and UV–vis spectroscopy methods to characterize the size, polydispersity index, zeta potential, encapsulation efficiency, loading capacity, and in vitro drug release of the synthesized nanoparticles. The CCK-8 cell viability test was used to study colorectal cancer cell growth in vitro. Results: We showed that CASIN-PLGA-PEG-COOH NPs were smooth, spherical, and had a particle size of 86 ± 1 nm, with an encapsulation efficiency of 66 ± 5% and a drug-loading capacity of 5 ± 1%. CASIN was gradually released from NPs, reaching its peak after 24 h, and could effectively inhibit the proliferation of HT-29 (IC50 = 19.55 µM), SW620 (IC50 = 9.33 µM), and HCT116 (IC50 = 10.45 µM) cells in concentrations ranging between 0.025–0.375 mg/mL. CASIN-PLGA-PEG-COOH NPs demonstrated low hemolytic activity with a hemolytic ratio of less than 1% for all tested concentrations. Conclusion: CASIN-PLGA-PEG-COOH NPs have high encapsulation efficiency, sustained drug release, good hemocompatibility, and antitumor activity in vitro. Our results suggest that PLGA-PEG-COOH nanoparticles loaded with CASIN show potential as a targeted treatment for colorectal cancer and could be recommended for further in vivo evaluation. Keywords: Cdc42; CASIN; colorectal cancer; PLGA-PEG-COOH; nanoparticles”

PLGA-PEG-COOH (Cat# AI078): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AI078#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

PCL from PolySciTech used in development of nano-polyhedron drug delivery platform.

Monday, October 14, 2024, 4:22 PM ET

Combinations of metal compounds with polymers can enable unique drug-delivery options. Researchers at China Three Gorges University used PCL (AP257) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to create mixed nanoparticles containing selenium and Riboflavin as a model drug delivery system. This research holds promise to provide for a wide array of targeted delivery applications. Read more: Zhu, Lixian, Yanhua Wang, Luping Rao, and Xin Yu. "Se-incorporated polycaprolactone spherical polyhedron enhanced vitamin B2 loading and prolonged release for potential application in proliferative skin disorders." Colloids and Surfaces B: Biointerfaces 245 (2025): 114295. https://www.sciencedirect.com/science/article/pii/S092777652400554X

“Highlights: The introduction of Se into PCL@VitB2 spherical polyhedrons reduces their particle size and crystallinity. Se-PCL spherical polyhedrons perform higher loading efficiency for Vitamin B2 than pure PCL spherical polyhedrons. Se-PCL@VitB2 spherical polyhedrons exhibit slowly prolonged Vitamin B2 release in physical buffers. Se-PCL@VitB2 spherical polyhedrons present strong inhibitory effect on the growth of epidermal HaCat cells, but are compatible to BMSC cells. Abstract: Development of novel drug vehicles for vitamin B2 (VitB2) delivery is very important for designing controllable release system to improve epidermal growth and bone metabolism. In this work, selenium (Se)-incorporated polycaprolactone (PCL) spherical polyhedrons are successfully synthesized via a single emulsion solvent evaporation method which is utilized to load VitB2 to fabricate cell-responsive Se-PCL@VitB2 delivery systems. Their physicochemical properties are characterized by DLS, SEM, XRD, FTIR, and TGA-DSC. The release kinetics of VitB2 or Se from the samples are investigated in PBS solution (pH = 2.0, 5.0, 7.4, 8.0 and 12.0). The cytocompatibilities are also evaluated with normal BMSC and epidermal HaCat cells. Results exhibit that Se-PCL@VitB2 particles presents spherical polyhedral morphology (approximately (3.25 ± 0.46) μm), negative surface charge (-(54.03 ± 2.94) mV), reduced crystallinity and good degradability. Stability experiments imply that both VitB2 and Se might be uniformly dispersed in PCL matrix. And the incorporation of Se facilely promotes the loading of VitB2. The encapsulation efficiency and loading capacity are (98.42 ± 1.06)% and (76.25 ± 1.27) for Se-PCL@VitB2 sample. Importantly, it exhibits more prolonged release of both VitB2 and Se in neutral PBS solution (pH = 7.4) than other pH conditions. Presumably, the electrostatic interaction between Se, VitB2 and PCL contribute to its release mode. Cell experiments show that Se-PCL@VitB2 presents strong cytotoxicity to HaCat cells mainly due to the cytotoxic effect of Se anions and PCL degradation products. However, it exhibits weak inhibitory effect on BMSC cells. These note that the synthesized Se-PCL@VitB2 particles can be promising drug vehicles for potential application in epidermal proliferative disorders.”

PCL (Cat# AP257): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AP257#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

PLGA-PEG-Maleimide and PEG-PLGA used in development of nanoparticles for oral delivery of semaglutide

Monday, October 14, 2024, 4:21 PM ET

GLP1 agonists are widely used in treatment of diabetes and other disease states. These drugs have poor oral bioavailability. Researchers at Universidade do Porto, Novo Nordisk, KTH Royal Institute of Technology, Roslagstullsbacken, University of Groningen used PLGA-PEG-Mal (AI110) and mPEG-PLGA (AK106) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to develop nanoparticles to pass through the intestine to provide for oral delivery of semaglutide. This research holds promise to provide for improved treatment of diabetes. Read more: Pinto, Soraia, Juliana Viegas, Cecília Cristelo, Catarina Pacheco, Sofia Barros, Stephen T. Buckley, Javad Garousi, Torbjörn Gräslund, Hélder A. Santos, and Bruno Sarmento. "Bioengineered Nanomedicines Targeting the Intestinal Fc Receptor Achieve the Improved Glucoregulatory Effect of Semaglutide in a Type 2 Diabetic Mice Model." ACS nano (2024). https://pubs.acs.org/doi/abs/10.1021/acsnano.4c11172

“The oral administration of the glucagon-like peptide-1 analogue, semaglutide, remains a hurdle due to its limited bioavailability. Herein, neonatal Fc receptor (FcRn)-targeted nanoparticles (NPs) were designed to enhance the oral delivery of semaglutide. The nanocarriers were covalently linked to the FcRn-binding peptide FcBP or the affibody molecule ZFcRn that specifically binds to the human FcRn (hFcRn) in a pH-dependent manner. These FcRn-targeted ligands were selected over the endogenous ligands of the receptor (albumin and IgG) due to their smaller size and simpler structure, which could facilitate the transport of functionalized NPs through the tissues. The capacity of FcRn-targeted semaglutide-NPs in controlling the blood glucose levels was evaluated in an hFcRn transgenic mice model, where type 2 diabetes mellitus (T2DM) was induced via intraperitoneal injection of nicotinamide followed by streptozotocin. The encapsulation of semaglutide into FcRn-targeted NPs was translated in an improved glucoregulatory effect in T2DM-induced mice when compared to the oral free semaglutide or nontargeted NP groups, after daily oral administrations for 7 days. Notably, a similar glucose-lowering response was observed between both FcRn-targeted NPs and the subcutaneous semaglutide groups. An increase in insulin pancreatic content and a recovery in β cell mass were visualized in the mice treated with FcRn-targeted semaglutide-NPs. The biodistribution of fluorescently labeled NPs through the gastrointestinal tract demonstrated that the nanosystems targeting the hFcRn are retained longer in the ileum and colorectum, where the expression of FcRn is more prevalent, than nontargeted NPs. Therefore, FcRn-targeted nanocarriers proved to be an effective platform for improving the pharmacological effect of semaglutide in a T2DM-induced mice model.”

PEG-PLGA (Cat# AK106): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AK106#h

PLGA-PEG-Mal (Cat# AI110): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AI110#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

PLGA-PEG-amine from PolySciTech used in development of nanoparticles for brain-tissue penetration

Monday, September 30, 2024, 2:11 PM ET

Delivery of medicinal molecules into the brain is difficult due to the blood-brain-barrier. Researchers at University of Technology Sydney and The University of Adelaide used PLGA-PEG-NH2 (AI058) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to develop nanoparticles enveloped in a protein corona. They used these particles to investigate mechanisms of uptake and delivery in brain tissue. This research holds promise to provide for improved therapies against brain diseases such as cancer and Alzheimer’s. Read more: Morshed, Nabila, Claire Rennie, Wei Deng, Lyndsey Collins-Praino, and Andrew Care. "Serum-derived protein coronas affect nanoparticle interactions with brain cells." Nanotechnology 35, no. 49 (2024): 495101. https://new.iopscience.iop.org/article/10.1088/1361-6528/ad7b40

“Neuronanomedicine is an emerging field bridging the gap between neuromedicine and novel nanotherapeutics. Despite promise, clinical translation of neuronanomedicine remains elusive, possibly due to a dearth of information regarding the effect of the protein corona on these neuronanomedicines. The protein corona, a layer of proteins adsorbed to nanoparticles following exposure to biological fluids, ultimately determines the fate of nanoparticles in biological systems, dictating nanoparticle–cell interactions. To date, few studies have investigated the effect of the protein corona on interactions with brain-derived cells, an important consideration for the development of neuronanomedicines. Here, two polymeric nanoparticles, poly(lactic-co-glycolic acid) (PLGA) and PLGA-polyethylene glycol (PLGA-PEG), were used to obtain serum-derived protein coronas. Protein corona characterization and liquid chromatography mass spectrometry analysis revealed distinct differences in biophysical properties and protein composition. PLGA protein coronas contained high abundance of globins (60%) and apolipoproteins (21%), while PLGA-PEG protein coronas contained fewer globins (42%) and high abundance of protease inhibitors (28%). Corona coated PLGA nanoparticles were readily internalized into microglia and neuronal cells, but not into astrocytes. Internalization of nanoparticles was associated with pro-inflammatory cytokine release and decreased neuronal cell viability, however, viability was rescued in cells treated with corona coated nanoparticles. These results showcase the importance of the protein corona in mediating nanoparticle–cell interactions.”

PLGA-PEG-Mal (Cat# AI058): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AI058#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

Video link: https://youtu.be/d3Z4GLgzcss

Network Upgrade Outage

Thursday, September 19, 2024, 10:20 AM ET

Notice: Akina, Inc. orders placed after 12:00 pm EST, Thursday, September 19th and Friday, September 20th, 2024 may experience delay as we migrate to a new internal server. We expect to resume fulfillment no later than Monday morning, September 23rd, 2024.

PLGA from PolySciTech used in development of nanoparticles for treatment of atherosclerosis

Tuesday, September 17, 2024, 4:53 PM ET

Atherosclerosis (heart-disease) is due to formation of lipid-laden plaques in the arteries. These plaques typically express immunosuppressive signals which prevents their removal by immune system. Recently, researchers at University of Ottawa utilized PLGA (AP023) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to develop nanoparticles to deliver immunotargeting compounds to plaques. This research holds promise as a potential treatment for heart disease. Read more: Patel, Yukta, Shireesha Manturthi, Saras Tiwari, Esha Gahunia, Amandine Courtemanche, Michelle Gandelman, Marceline Côté, and Suresh Gadde. "Development of Pro-resolving and Pro-efferocytic Nanoparticles for Atherosclerosis Therapy." ACS Pharmacology & Translational Science (2024). https://pubs.acs.org/doi/abs/10.1021/acsptsci.4c00292

“Atherosclerosis is a major contributor to cardiovascular diseases with a high global prevalence. It is characterized by the formation of lipid-laden plaques in the arteries, which eventually lead to plaque rupture and thrombosis. While the current lipid-lowering therapies are generally effective in lowering the risk of cardiovascular events, they do not address the underlying causes of disease. Defective resolution of inflammation and impaired efferocytosis are the main driving forces of atherosclerosis. Macrophages recognize cells for clearance by the expression of “eat me” and “do not eat me” signals, including the CD47-SIRPα axis. However, the “do not eat me” signal CD47 is overexpressed in atherosclerotic plaques, leading to compromised efferocytosis and secondary necrosis. In this context, prophagocytic antibodies have been explored to stimulate the clearance of apoptotic cells, but they are nonspecific and impact healthy tissues. In macrophages, downstream of signal regulatory protein α, lie protein tyrosine phosphatases, SHP 1/2, which can serve as effective targets for selectively phagocytosing apoptotic cells. While increasing the efferocytosis targets the end stages of lesion development, the underlying issue of inflammation still persists. Simultaneously increasing efferocytosis and reducing inflammation can be effective therapeutic strategies for managing atherosclerosis. For instance, IL-10 is a key anti-inflammatory mediator that enhances efferocytosis via phosphoSTAT3 (pSTAT3) activation. In this study, we developed a combination nanotherapy by encapsulating an SHP-1 inhibitor (NSC 87877) and IL-10 in a single nanoparticle platform [(S + IL)-NPs] to enhance efferocytosis and inflammation resolution. Our studies suggest that (S + IL)-NPs successfully encapsulated both agents, entered the macrophages, and delivered the agents into intracellular compartments. Additionally, (S + IL)-NPs decreased inflammation by suppressing pro-inflammatory markers and enhancing anti-inflammatory mediators. They also exhibited the potential for improved phagocytic activity via pSTAT3 activation. Our nanomedicine-mediated upregulation of the anti-inflammatory and efferocytic responses in macrophages shows promise for the treatment of atherosclerosis.”

PLGA-PEG-Mal (Cat# AP023): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AP023#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

Video: https://youtu.be/2iOHeKrPL34

PLGA-PEG-Mal from PolySciTech used in development of nano-delivery system for glioblastoma treatment

Tuesday, September 17, 2024, 4:53 PM ET

Glioblastoma is an aggressive brain cancer that is difficult to treat. Researchers at Southern University of Science and Technology, University of Texas Southwestern Medical Center, Xuzhou Medical University used PLGA-PEG-Maleimide (AI110) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to develop nanoparticles for targeting glioblastoma. They utilized this as part of a multifunctional system to maximize both radiotherapy and also immunotherapy against glioblastoma. Read more: Wen, Xin, Zhiying Shao, Xueting Chen, Hongmei Liu, Hui Qiu, Xin Ding, Debao Qu, Hui Wang, Andrew Z. Wang, and Longzhen Zhang. "A multifunctional targeted nano-delivery system with radiosensitization and immune activation in glioblastoma." Radiation Oncology 19, no. 1 (2024): 1-20. https://ro-journal.biomedcentral.com/articles/10.1186/s13014-024-02511-9

“Glioblastoma (GBM), the most common primary brain malignancy in adults, is notoriously difficult to treat due to several factors: tendency to be radiation resistant, the presence of the blood brain barrier (BBB) which limits drug delivery and immune-privileged status which hampers effective immune responses. Traditionally, high-dose irradiation (8 Gy) is known to effectively enhance anti-tumor immune responses, but its application is limited by the risk of severe brain damage. Currently, conventional dose segmentation (2 Gy) is the standard radiotherapy method, which does not fully exploit the potential of high-dose irradiation for immune activation. The hypothesis of our study posits that instead of directly applying high doses of radiation, which is risky, a strategy could be developed to harness the immune-stimulating benefits of high-dose irradiation indirectly. This involves using nanoparticles to enhance antigen presentation and immune responses in a safer manner. Angiopep-2 (A2) was proved a satisfactory BBB and brain targeting and Dbait is a small molecule that hijack DNA double strand break damage (DSB) repair proteins to make cancer cells more sensitive to radiation. In view of that, the following two nanoparticles were designed to combine immunity of GBM, radiation resistance and BBB innovatively. One is cationic liposome nanoparticle interacting with Dbait (A2-CL/Dbait NPs) for radiosensitization effect; the other is PLGA-PEG-Mal nanoparticle conjugated with OX40 antibody (A2-PLGA-PEG-Mal/anti-OX40 NPs) for tumor-derived protein antigens capture and optimistic immunoregulatory effect of anti-OX40 (which is known to enhance the activation and proliferation T cells). Both types of nanoparticles showed favorable targeting and low toxicity in experimental models. Specifically, the combination of A2-CL/Dbait NPs and A2-PLGA-PEG-Mal/anti-OX40 NPs led to a significant extension in the survival time and a significant tumor shrinkage of mice with GBM. The study demonstrates that combining these innovative nanoparticles with conventional radiotherapy can effectively address key challenges in GBM treatment. It represents a significant step toward more effective and safer therapeutic options for GBM patients.”

PLGA-PEG-Mal (Cat# AI110): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AI110#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

Video: https://youtu.be/jLCzFHNPN2c

PLGA-PEG-PLGA Thermogels from PolySciTech used in development of controlled antibody release system

Tuesday, September 17, 2024, 4:52 PM ET

Thermogels have the ability to dissolve in cold water and form solid, gel structures when heated to body temperature. This allows them to deliver delicate molecules, like antibodies, which typically break down under normal processing conditions to form microparticles. Researchers at the Polish Academy of Sciences used PLGA-PEG-PLGA (AK012, AK024, AK088, AK091) and PLCL-PEG-PLCL (AK108) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to create a gel to deliver antibodies. This research holds promise to provide for improved biotherapy techniques in the future. Read more: Lipowska-Kur, Daria, Łukasz Otulakowski, Urszula Szeluga, Katarzyna Jelonek, and Alicja Utrata-Wesołek. "Diverse Strategies to Develop Poly (ethylene glycol)–Polyester Thermogels for Modulating the Release of Antibodies." Materials 17, no. 18 (2024): 4472. https://www.mdpi.com/1996-1944/17/18/4472

“Abstract: In this work, we present basic research on developing thermogel carriers containing high amounts of model antibody immunoglobulin G (IgG) with potential use as injectable molecules. The quantities of IgG loaded into the gel were varied to evaluate the possibility of tuning the dose release. The gel materials were based on blends of thermoresponsive and degradable ABA-type block copolymers composed of poly(lactide-co-glycolide)-b-poly(ethylene glycol)-b-poly(lactide-co-glycolide) (PLGA–PEG–PLGA) or poly(lactide-co-caprolactone)-b-poly(ethylene glycol)-b-(lactide-co-caprolactone) (PLCL–PEG–PLCL). Primarily, the gels with various amounts of IgG were obtained via thermogelation, where the only factor inducing gel formation was the change in temperature. Next, to control the gels’ mechanical properties, degradation rate, and the extent of antibody release, we have tested two approaches. The first one involved the synergistic physical and chemical crosslinking of the copolymers. To achieve this, the hydroxyl groups located at the ends of the PLGA–PEG–PLGA chain were modified into acrylate groups. In this case, the thermogelation was accompanied by chemical crosslinking through the Michael addition reaction. Such an approach increased the dynamic mechanical properties of the gels and simultaneously prolonged their decomposition time. An alternative solution was to suspend crosslinked PEG–polyester nanoparticles loaded with IgG in a PLGA–PEG–PLGA gelling copolymer. We observed that loading IgG into thermogels lowered the gelation temperature (TGEL) value and increased the storage modulus of the gels, as compared with gels without IgG. The prepared gel materials were able to release the IgG from 8 up to 80 days, depending on the gel formulation and on the amount of loaded IgG. The results revealed that additional, chemical crosslinking of the thermogels and also suspension of particles in the polymer matrix substantially extended the duration of IgG release. With proper matching of the gel composition, environmental conditions, and the type and amount of active substances, antibody-containing thermogels can serve as effective IgG delivery materials. Keywords: thermogels; sol-gel transition; tandem gelation; polymer degradation; nanoparticles; antibody”

PLCL-PEG-PLCL (Cat# AK108): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AK108#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

Video: https://youtu.be/bwM2c-jwuSI

PLCL-PEG-PLCL from PolySciTech used in exploration of tumor cytokine interactions

Monday, August 19, 2024, 4:53 PM ET

Despite years of research, the biological and cellular mechanisms of cancer are not fully understood. Understanding the complex biological pathways and cascades involved in cancer growth and, notably, immunosuppression can unlock potential targets for cancer-specific therapies. Researchers at Johns Hopkins University, Stanford University, University of Ulsan, used PLCL-PEG-PLCL (AK109) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to create a gel for delivery of METRNL cytokine as a means to explore the interaction of this cytokine with tumor cells. This research holds promise to improve immunotherapy approaches in the future. Read more: Jackson, Christopher M., Ayush Pant, Wikum Dinalankara, John Choi, Aanchal Jain, Ryan Nitta, Eli Yazigi et al. "The cytokine Meteorin-like inhibits anti-tumor CD8+ T cell responses by disrupting mitochondrial function." Immunity (2024). https://www.cell.com/immunity/abstract/S1074-7613(24)00352-2

“Tumor-infiltrating lymphocyte (TIL) hypofunction contributes to the progression of advanced cancers and is a frequent target of immunotherapy. Emerging evidence indicates that metabolic insufficiency drives T cell hypofunction during tonic stimulation, but the signals that initiate metabolic reprogramming in this context are largely unknown. Here, we found that Meteorin-like (METRNL), a metabolically active cytokine secreted by immune cells in the tumor microenvironment (TME), induced bioenergetic failure of CD8+ T cells. METRNL was secreted by CD8+ T cells during repeated stimulation and acted via both autocrine and paracrine signaling. Mechanistically, METRNL increased E2F-peroxisome proliferator-activated receptor delta (PPARd) activity, causingmitochondrial depolarization and decreased oxidative phosphorylation, which triggered a compensatory bioenergetic shift to glycolysis. Metrnl ablation or downregulation improved the metabolic fitness of CD8+ T cells and enhanced tumor control in several tumor models, demonstrating the translational potential of targeting the METRNL-E2F-PPARd pathway to support bioenergetic fitness of CD8+ TILs.”

PLCL-PEG-PLCL (Cat# AK109): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AK109#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

PLCL from PolySciTech used in development of Neural Interface system

Monday, August 19, 2024, 4:47 PM ET

Developing the ability to interface between brain signals and digital equipment can be highly useful for patients suffering from paralysis or other disease states limiting their bodily mobility. Researchers at Seoul National University, Dankook University, University of Ulsan, Kwangwoon University, Korea University, Northwestern University, Gyeongsang National University, Sungkyunkwan University used PLCL (AP067) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to create a biocompatible and flexible structure for minimally invasive implantation of a neural interface. This research holds promise to provide for improved prosthetics and other human-digital interfaces in the future. Read more: Bae, Jae-Young, Gyeong-Seok Hwang, Young-Seo Kim, Jooik Jeon, Minseong Chae, Joon-Woo Kim, Sian Lee et al. "A biodegradable and self-deployable electronic tent electrode for brain cortex interfacing." Nature Electronics (2024): 1-14. https://www.nature.com/articles/s41928-024-01216-x

“High-density, large-area electronic interfaces are a key component of brain–computer interface technologies. However, current designs typically require patients to undergo invasive procedures, which can lead to various complications. Here, we report a biodegradable and self-deployable tent electrode for brain cortex interfacing. The system can be integrated with multiplexing arrays and a wireless module for near-field communication and data transfer. It can be programmably packaged and self-deployed using a syringe for minimally invasive delivery through a small hole. Following delivery, it can expand to cover an area around 200 times its initial size. The electrode also naturally decomposes within the body after use, minimizing the impact of subsequent removal surgery. Through in vivo demonstrations, we show that our cortical-interfacing platform can be used to stimulate large populations of cortical activities.”

PLCL (Cat# AP067): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AP067#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

PLGA-PEG-PLGA from PolySciTech used in evaluation of cytotoxicity test applicability

Thursday, August 15, 2024, 3:43 PM ET

In-vitro cytotoxicity tests are conducted as a surrogate for in-vivo testing to determine if a material has toxicity by monitoring its interactions with cells. Researchers at University of Nottingham utilized PLGA-PEG-PLGA (Cat# AK097) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to evaluate the interaction of this product with cells following the cytotoxicity tests. They found that the methodology applied for the test is important as the polymer exhibits acidic formation and other properties which yield false positives for cytotoxicity when no toxic effects are observed in animal model. This research holds promise to improve the methodology applied for evaluating toxicity of hydrogel materials. Read more: Stewart, Chloe L., Andrew L. Hook, Mischa Zelzer, Maria Marlow, and Anna M. Piccinini. "PLGA‐PEG‐PLGA hydrogels induce cytotoxicity in conventional in vitro assays." Cell Biochemistry and Function 42, no. 5 (2024): e4097. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cbf.4097

“We identified that PLGA-PEG-PLGA hydrogels, which have been used in human clinical trials and possess a demonstrable safety profile, induced significant cytotoxicity in conventional in vitro assays. This major contradiction may lead to inconsistent and misleading toxicology due to the limited biological representation of these assays. Cytotoxicity evaluation is a crucial element of screening the biological response to new biomaterials. However, as standard test methods do not recapitulate the in vivo environment, tailored adaptations may be required to reflect the true biological response elicited toward novel biomaterials.”

PLGA-PEG-PLGA (Cat# AK097): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AK097#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

Video: https://youtu.be/BB3q7G8FVeY

PLA from PolySciTech used in development of inulin-PLA copolymers for drug delivery

Tuesday, August 6, 2024, 4:00 PM ET

Inulin, a water-soluble polysaccharide from plants, can be used as a biomaterial for drug delivery and other applications. Researchers at University of Salerno, University of Naples Federico II, and Polish Academy of Sciences used two sizes of PLA (Cat # AP005, AP079) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to synthesize inulin-PLA. This research holds promise to provide for novel methods of drug delivery. Read more: Sardo, C., G. Auriemma, C. Mazzacano, C. Conte, V. Piccolo, T. Ciaglia, M. Denel-Bobrowska, A. B. Olejniczak, D. Fiore, and M. C. Proto. "Inulin Amphiphilic Copolymer-Based Drug Delivery: Unraveling the Structural Features of Graft Constructs.” Pharmaceutics 2024, 16, 971. https://www.mdpi.com/1999-4923/16/8/971

“In this study, the structural attributes of nanoparticles obtained by a renewable and nonimmunogenic “inulinated” analog of the “pegylated” PLA (PEG-PLA) were examined, together with the potential of these novel nanocarriers in delivering poorly water-soluble drugs. Characterization of INU-PLA assemblies, encompassing critical aggregation concentration (CAC), NMR, DLS, LDE, and SEManalyses, was conducted to elucidate the core/shell architecture of the carriers and in vitro cytoand hemo-compatibility were assayed. The entrapment and in vitro delivery of sorafenib tosylate (ST) were also studied. INU-PLA copolymers exhibit distinctive features: (1) Crew-cut aggregates are formed with coronas of 2–4 nm; (2) a threshold surface density of 1 INU/nm2 triggers a configuration change; (3) INU surface density influences PLA core dynamics, with hydrophilic segment stretching affecting PLA distribution towards the interface. INU-PLA2 NPs demonstrated an outstanding loading of ST and excellent biological profile, with effective internalization and ST delivery to HepG2 cells, yielding a comparable IC50.”

PLA (Cat# AP005): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AP005#h

PLA (Cat# AP079): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AP079#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

PEG-PLGA from PolySciTech used in development of triple-chemotherapy loaded nanoparticles

Tuesday, August 6, 2024, 3:59 PM ET

Cancer is a complex disease often requiring multiple drugs to elicit effective treatment. Researchers at University of Ottawa and University of Toronto used mPEG-PLGA (Cat# AK148) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to create nanoparticles loaded with cisplatin, olaparib, and metformin for cancer therapy. This research holds promise to improve treatment of cancer. Read more: Durocher, Emma, Sean McGrath, Esha Gahunia, Naomi Matsuura, and Suresh Gadde. "Development of 3-in-1 nanotherapeutic strategies for ovarian cancer." bioRxiv (2024): 2024-07. https://www.biorxiv.org/content/10.1101/2024.07.17.604002.abstract

“Among gynecological cancers, ovarian cancer causes the most fatality. Platin-based chemotherapy is the primary therapeutic option, but it is limited by a variety of drug resistance mechanisms. Ovarian cancer is a complex and challenging disease to treat, and combination approaches have shown stronger efficacy than a single drug alone. However, they still need to overcome challenges, such as the non-selective distribution of drugs, and side effects caused by each drug in the combination. To overcome these issues, here we explored a 3-in-1 combination nanotherapeutic approach containing cisplatin, olaparib, and metformin for ovarian cancer. To encapsulate hydrophilic cisplatin and metformin inside the nanoparticle (NP) core, we developed cisplatin polymer prodrugs and metformin derivatives. Our results showed successful development of 3-in-1 NPs containing cisplatin, olaparib, and metformin, and they are stable in the physiological conditions. In vitro evaluation showed each agent in the 3-in-1 NPs is active and exerts therapeutic effects, contributing to ovarian cancer cell killing at lower concentrations. These results provide insight into developing novel nanotherapeutic strategies for improving ovarian cancer treatment.”

mPEG-PLGA (Cat# AK148): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AK148#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

Video: https://youtu.be/WcgTeg291Kw

PLGA-PEG-Mal and PLGA-FKR648 from PolySciTech used in development of Mucin-16 cancer targeted nanoparticles

Tuesday, July 23, 2024, 8:32 AM ET

Targeting to cancer relies on differences between healthy cells and cancerous ones. For example, differences in mucin 16 can be used as a target moiety for drug delivery. Researchers at University of Portugal used PLGA-PEG-Mal (Cat# AI110) and PLGA-FKR648 (Cat# AV015) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to create nanoparticles with mucin-based targeting for cancer therapy. This research holds promise to improve cancer treatments in the future. Read more: Freitas, Rui, Eduardo Ferreira, Andreia Miranda, Dylan Ferreira, Marta Relvas-Santos, Flávia Castro, Beatriz Santos et al. "Targeted and Self-Adjuvated Nanoglycovaccine Candidate for Cancer Immunotherapy." ACS nano 18, no. 14 (2024): 10088-10103. https://pubs.acs.org/doi/abs/10.1021/acsnano.3c12487

“Advanced-stage solid primary tumors and metastases often express mucin 16 (MUC16), carrying immature glycans such as the Tn antigen, resulting in specific glycoproteoforms not found in healthy human tissues. This presents a valuable approach for designing targeted therapeutics, including cancer glycovaccines, which could potentially promote antigen recognition and foster the immune response to control disease spread and prevent relapse. In this study, we describe an adjuvant-free poly(lactic-co-glycolic acid) (PLGA)-based nanoglycoantigen delivery approach that outperforms conventional methods by eliminating the need for protein carriers while exhibiting targeted and adjuvant properties. To achieve this, we synthesized a library of MUC16-Tn glycoepitopes through single-pot enzymatic glycosylation, which were then stably engrafted onto the surface of PLGA nanoparticles, generating multivalent constructs that better represent cancer molecular heterogeneity. These glycoconstructs demonstrated affinity for Macrophage Galactose-type Lectin (MGL) receptor, known to be highly expressed by immature antigen-presenting cells, enabling precise targeting of immune cells. Moreover, the glycopeptide-grafted nanovaccine candidate displayed minimal cytotoxicity and induced the activation of dendritic cells in vitro, even in the absence of an adjuvant. In vivo, the formulated nanovaccine candidate was also nontoxic and elicited the production of IgG specifically targeting MUC16 and MUC16-Tn glycoproteoforms in cancer cells and tumors, offering potential for precise cancer targeting, including targeted immunotherapies. KEYWORDS: glycovaccines nanovaccines cancer immunotherapy cancer glycosylation glycoantigens glycoconjugates”

PLGA-PEG-Mal (Cat# AI110): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AI110#h

PLGA-FKR648 (Cat# AV015): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AV015#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

PEG-PLGA and PLGA-NHS from PolySciTech used in development of cancer targeting nanoparticles

Tuesday, July 23, 2024, 8:31 AM ET

Prostate cancer accounts for 14.9% of all new cancer cases. Researchers from Howard University used PEG-PLGA (Cat# AK029) and PLGA-NHS (Cat# AI097) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to create nanoparticles with PSMA targeting to prostate cancer cells. This research holds promise to provide for treatment of cancer. Read more: Adekiya, Tayo Alex, Tamaro Hudson, Oladapo Bakare, Edmund E. Ameyaw, Amusa Adebayo, Oluwabukunmi Olajubutu, and Simeon K. Adesina. "PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer." Biomedicine & Pharmacotherapy 177 (2024): 117125. https://www.sciencedirect.com/science/article/pii/S0753332224010096

“Highlights: PSMA-targeting facilitates prostate cancer-specific drug delivery. 10 % nanoparticle surface density of PSMA targeting ligand is optimal for uptake. PSMA-targeted drug-loaded particles show cytotoxicity to the cell lines tested. PSMA-targeted nanoparticles suppress tumor growth in xenograft models. Brusatol-containing nanoparticle formulations aid reduction in tumor volume. Abstract: Active targeting to cancer involves exploiting specific interactions between receptors on the surface of cancer cells and targeting moieties conjugated to the surface of vectors such that site-specific delivery is achieved. Prostate specific membrane antigen (PSMA) has proved to be an excellent target for active targeting to prostate cancer. We report the synthesis and use of a PSMA-specific ligand (Glu-NH-CO-NH-Lys) for the site-specific delivery of brusatol- and docetaxel-loaded poly(lactide-co-glycolide) (PLGA) nanoparticles to prostate cancer. The PSMA targeting ligand covalently linked to PLGA-PEG3400 was blended with methoxyPEG-PLGA to prepare brusatol- and docetaxel-loaded nanoparticles with different surface densities of the targeting ligand. Flow cytometry was used to evaluate the impact of different surface densities of the PSMA targeting ligand in LNCaP prostate cancer cells at 15 min and 2 h. Cytotoxicity evaluations of the targeted nanoparticles reveal differences based on PSMA expression in PC-3 and LNCaP cells. In addition, levels of reactive oxygen species (ROS) were measured using the fluorescent indicator, H2DCFDA, by flow cytometry. PSMA-targeted nanoparticles loaded with docetaxel and brusatol showed increased ROS generation in LNCaP cells compared to PC-3 at different time points. Furthermore, the targeted nanoparticles were evaluated in male athymic BALB/c mice implanted with PSMA-producing LNCaP cell tumors. Evaluation of the percent relative tumor volume show that brusatol-containing nanoparticles show great promise in inhibiting tumor growth. Our data also suggest that the dual drug-loaded targeted nanoparticle platform improves the efficacy of docetaxel in male athymic BALB/c mice implanted with PSMA-producing LNCaP cell tumors.”

PEG-PLGA (Cat# AK029): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AK029#h

PLGA-NHS (Cat# AI097): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AI097#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

PLGA from PolySciTech used in development of ultrasound triggered delivery of genes for bone cancer treatment

Tuesday, July 23, 2024, 8:30 AM ET

Bone cancer is particularly difficult to treat due to its poor response to conventional chemotherapy and other, non-surgical, methods. Researchers at Chongqing Medical University used PLGA (cat# AP041) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to create nanobubbles for transfer of genes into target cells using ultrasound. This research holds promise to provide for non-invasive therapies for bone cancer. Read more: Ren, Honglei, Shanlin Xiang, Aiguo Liu, Qian Wang, Nian Zhou, and Zhenming Hu. "A noval noninvasive targeted therapy for osteosarcoma: the combination of LIFU and ultrasound-magnetic-mediated SPIO/TP53/PLGA nanobubble." Frontiers in Bioengineering and Biotechnology 12 (2024): 1418903. https://www.frontiersin.org/articles/10.3389/fbioe.2024.1418903/full

“Purpose: Osteosarcoma (OS) is the most common type of primary malignant bone tumor. Transducing a functional TP53 gene can effectively inhibit OS cell activity. Poly lactic acid-glycolic acid (PLGA) nanobubbles (NBs) mediated by focused ultrasound (US) can introduce exogenous genes into target cells in animal models, but this technique relies on the passive free diffusion of agents across the body. The inclusion of superparamagnetic iron oxide (SPIO) in microbubbles allows for magnetic-based tissue localization. A low-intensity-focused ultrasound (LIFU) instrument was developed at our institute, and different intensities of LIFU can either disrupt the NBs (RLI-LIFU) or exert cytocidal effects on the target tissues (RHI-LIFU). Based on these data, we performed US-magnetic-mediated TP53-NB destruction and investigated its ability to inhibit OS growth when combined with LIFU both in vitro and in vivo. Methods: Several SPIO/TP53/PLGA (STP) NB variants were prepared and characterized. For the in vitro experiments, HOS and MG63 cells were randomly assigned into five treatment groups. Cell proliferation and the expression of TP53 were detected by CCK8, qRT-PCR and Western blotting, respectively. In vivo, tumor-bearing nude mice were randomly assigned into seven treatment groups. The iron distribution of Perls’ Prussian blue-stained tissue sections was determined by optical microscopy. TUNEL-DAPI was performed to examine apoptosis. TP53 expression was detected by qRT-PCR and immunohistochemistry. Results: SPIO/TP53/PLGA NBs with a particle size of approximately 200 nm were prepared successfully. For in vitro experiments, ultrasound-targeted transfection of TP53 overexpression in OS cells and efficient inhibition of OS proliferation have been demonstrated. Furthermore, in a tumor-bearing nude mouse model, RLI-LIFU-magnetic-mediated SPIO/TP53/PLGA NBs increased the transfection efficiency of the TP53 plasmid, resulting in apoptosis. Adding RHI-LIFU to the treatment regimen significantly increased the apoptosis of OS cells in vivo. Conclusion: Combining LIFU and US-magnetic-mediated SPIO/TP53/PLGA NB destruction is potentially a novel noninvasive and targeted therapy for OS.”

PEG-PLA AP041: https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AP041#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

PEG-PLGA from PolySciTech used in development of oral delivery system for Enfuvirtide as HIV treatment

Friday, July 19, 2024, 4:39 PM ET

Many antiviral agents have poor uptake across the intestine which limits them to only being administered by parental routes. For patient convenience, comfort, and compliance delivery by oral route is preferable. Researchers at The University of Queensland used PEG-PLGA (cat# AK026) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to create oral nanoparticles for delivery of Enfuvirtide as an antiviral agent. This research holds promise to provide additional treatment for HIV/AIDS. Read more: Pang, Huiwen, Zhi Qu, Vinod Kumar, Yinuo Wang, Youzhi Wu, Min‐Hsuan Lin, David Harrich, and Felicity Y. Han. "Novel Delivery Systems for Oral Administration of Enfuvirtide: New Treatment Options for HIV/AIDS." Advanced Therapeutics (2024): 2300439. https://onlinelibrary.wiley.com/doi/abs/10.1002/adtp.202300439

“Enfuvirtide (T-20) is a synthetic peptide fusion inhibitor for the human immunodeficiency virus (HIV), which causes acquired immunodeficiency syndrome (AIDS). However, the peptide nature limits a wider application of T-20 with subcutaneous injection (Fuzeon) the only available formulation. In this groundbreaking study, it is sought to overcome this limitation by employing poly lactic-co-glycolic acid (PLGA) and alginate to create novel oral delivery systems for T-20. Remarkably, this investigation marks the first instance of assessing the efficacy of oral delivery systems in mice. Notably, both the PLGA and alginate formulations exhibit the capability to sustain T-20 release, maintaining detectable levels in the bloodstream of mice for over 24 h after a single dose. By venturing into the realm of oral T-20 delivery, this study opens avenues for the prospective development of oral formulations of T-20, potentially leading to their evaluation in clinical trials.”

PEG-PLA AK026: https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AK026#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

PEG-PLA from PolySciTech used in development of intracranial delivery of drugs for brain treatment

Friday, July 19, 2024, 4:09 PM ET

Delivery of medicinal molecules into brain tissue is complicated by the blood-brain-barrier which prevents many drugs from crossing into the brain tissue. Researchers at University of Utah used PEG-PLA (cat# AK009) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to create nano emulsions which could be triggered through the cranium using ultrasound technology. This research holds promise to provide treatment for a variety of neurological conditions. Read more: Wilson, Matthew G., Thomas S. Riis, and Jan Kubanek. "Controlled ultrasonic interventions through the human skull." Frontiers in Human Neuroscience 18 (2024): 1412921. https://www.frontiersin.org/articles/10.3389/fnhum.2024.1412921/full

“Transcranial focused ultrasound enables precise and non-invasive manipulations of deep brain circuits in humans, promising to provide safe and effective treatments of various neurological and mental health conditions. Ultrasound focused to deep brain targets can be used to modulate neural activity directly or localize the release of psychoactive drugs. However, these applications have been impeded by a key barrier—the human skull, which attenuates ultrasound strongly and unpredictably. To address this issue, we have developed an ultrasound-based approach that directly measures and compensates for the ultrasound attenuation by the skull. No additional skull imaging, simulations, assumptions, or free parameters are necessary; the method measures the attenuation directly by emitting a pulse of ultrasound from an array on one side of the head and measuring with an array on the opposite side. Here, we apply this emerging method to two primary future uses—neuromodulation and local drug release. Specifically, we show that the correction enables effective stimulation of peripheral nerves and effective release of propofol from nanoparticle carriers through an ex vivo human skull. Neither application was effective without the correction. Moreover, the effects show the expected dose-response relationship and targeting specificity. This article highlights the need for precise control of ultrasound intensity within the skull and provides a direct and practical approach for addressing this lingering barrier.”

PEG-PLA AK009: https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AK009#h

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

These posts are syndicated from John Garner's blog at http://jgakinainc.blogspot.com/ where you can post a question or comment. (Load took 0.16984510421753 seconds)